Drusbosky, Leylah
ImmunityBio (United States)
2 papers on CoChatORCID 0000-0002-9401-4600
Most cited papers
- Verified
Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC
Negrao, M. V., Araujo, H. A., Lamberti, G., Cooper, A. J., Akhave, N. S., Zhou, T., Delasos, L., Hicks, J. K., Aldea, M., Minuti, G., et al. (2023) · Cancer Discovery
Lung Cancer Treatments and MutationsCancer Genomics and Diagnostics
Cited by 203
- Verified
Efficacy outcomes in first-line (1L) non–small cell lung cancer (NSCLC) with maintenance of immune competence: QUILT-2.023 randomized phase 3 study of IL-15R agonist nogapendekin alfa inbakicept (NAI) with checkpoint inhibitor (CPI) ± chemotherapy.
Wrangle, J. M., Dreisbach, L. P., Rao, A. R., Nangia, C. S., Lewis, C., Drusbosky, L., Bhar, P., Allinder, M., Reddy, S. B., & Soon-Shiong, P. (2026) · Journal of Clinical Oncology
Cancer Immunotherapy and BiomarkersLung Cancer Treatments and Mutations
Cited by 0
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free